A number of studies in the literature support the use of fine aerosols of drug, inhaled at low IFRs to target peripheral airways, with the objective of improving clinical responses to inhaled therapy (Fig. 8). Attempts have been made to separate response due to changes in total administered dose or the surface concentration of the dose from response due to changes in site of deposition-both are affected by the particle size of the aerosol, with IFR additionally influencing the latter.
MorrowPE, YuCP. Models of aerosol behavior in airways and alveoli. In: MorénF, DolovichMB, NewhouseMT, NewmanSP, editors. Aerosols in medicine: principles, diagnosis and therapy, 2nd ed. Amsterdam: Elsevier; 1993: 157–193.
4.
AutyRM, BrownK, NealeMG, SnashallPD. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br J Dis Chest1987;81(4):371–380.
5.
NewnhamDM, LipworthBJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax1994;49(8):762–770.
6.
WilsonAM, DempseyOJ, CoutieWJ, SimsEJ, LipworthBJ. Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids (letter). Lancet1999;353(9170):2128.
7.
LippmannM.Regional deposition of particles in the human respiratory tract. In: LeeDHK, FalkHL, MurphySD, editors. Handbook of physiology, Section 9, Reaction to environmental agents. Bethesda MD: American Physiological Society; 1977: 213–232.
8.
ChangHK, MenonAS. Airflow dynamics in the human airways. In: MorénF, DolovichMB, NewhouseMT, NewmanSP, editors. Aerosols in medicine: principles, diagnosis and therapy, 2nd ed. Amsterdam: Elsevier; 1993: 85–116.
9.
SmaldoneGC, MessinaMS. Flow limitation, cough, and patterns of aerosol deposition in humans. J Appl Physiol1985;59(2):515–520.
10.
RuffinRE, DolovichMB, WolffRK, NewhouseMT. The effects of preferential deposition of histamine in the human airway. Am Rev Respir Dis1978;117(3):485–492.
11.
JohnsonMA, NewmanSP, BloomR, TalaeeN, ClarkeSW. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma: efficacy and pulmonary deposition. Chest1989;96(1):6–10.
12.
DolovichM, RyanG, NewhouseMT. Aerosol penetration into the lung: influence on airway responses. Chest1981;80(6 Suppl):834–836.
13.
DickensGR, WermelingDP, MathenyCJ, JohnW, AbramowitzW, SistaSM, et al. Flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration (abstract). J Allergy Clin Immunol1999; 103 (1 Pt 2): Abstract 504.
14.
LipworthBJ, ClarkDJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulm Pharmacol Ther1997;10(4):211–214.
15.
ChrystynH.Anatomy and physiology in delivery: can we define our targets?Allergy1999;54 Suppl49:82–87.
16.
YuCP, TaulbeeDB. A theory of predicting respiratory tract deposition of inhaled particles in man. Inhaled Part1975;4 Pt1:35–47.
17.
GerrityTR, LeePS, HassFJ, MarinelliA, WernerP, LourencoRV. Calculated deposition of inhaled particles in the airway generations of normal subjects. J Appl Physiol1979;47(4):867–873.
18.
GondaI.A semi-empirical model of aerosol deposition in the human respiratory tract for mouth inhalation. J Pharm Pharmacol1981;33(11):692–696.
19.
GondaI.Scintigraphic techniques for measuring in vivo deposition. J Aerosol Med1996;9 Suppl1:S59–S67.
20.
MartonenTB, YangY, DolovichM.Definition of airway composition within gamma camera images. J Thorac Imaging1994;9(3):188–197.
21.
PhippsPR, GondaI, BaileyDL, BorhamP, BautovichG, AndersonSD. Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis1989;139(6):1516–1523.
22.
FlemingJS, HashishAH, ConwayJH, NassimMA, HolgateST, HalsonP, et al. Assessment of deposition of inhaled aerosol in the respiratory tract of man using three-dimensional multimodality imaging and mathematical modeling. J Aerosol Med1996;9(3):317–327.
SummersQA, FlemingJS, DaiY, PerringS, HoneywellR, GoughKJ, et al. The pulmonary deposition of two aerosol preparations of nedocromil sodium delivered by MDI assessed by single photon emission computed tomography. J Aerosol Med1996;9 Suppl1:S93–S109.
25.
OjimaF, IdoT, TakahashiT, HatazawaJ, IroM, SasakiH, et al. Preparation of a fine powder of 2-deoxy-2-[18F]fluoro-D-glucose suitable for inhalation to diagnose lung diseases by means of PET. Ann Nucl Med1989;3(3):143–147.
26.
BerridgeMS, HealdDL. In vivo characterization of inhaled pharmaceuticals using quantitative positron emission tomography. J Clin Pharmacol1999;Suppl:25S–29S.
27.
DolovichM, NahmiasC, ThompsonM, YukiS, FrietagA, CoatesG.Positron emission tomographic (PET) imaging of the lung in cystic fibrosis: 3D assessment of the distribution of inhaled therapy (abstract). Am J Respir Crit Care Med1999;159(4 Pt 2):A687.
28.
RahmanS, RhoadesCG, ConstantinouM, WatersS, AigbirhioFI, OsmanS, et al. Lung deposition of 18-F-fluticasone propionate in normal subjects using positron emission tomography therapy (abstract). Am J Respir Crit Care Med2000;161(4 Pt 2):A177.
29.
DolovichMB, SanchisJ, RossmanC, NewhouseMT. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol1976;40(3):468–471.
30.
DolovichM, RushbrookJ, ChurchillE, MazzaM, PowlesAC. Effect of continuous lateral rotational therapy on lung mucus transport in mechanically ventilated patients. J Crit Care1998;13(3):119–125.
31.
IlowiteJS, GorvoyJD, SnaldoneGC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis1987;136(6):1445–1449.
32.
LaubeBL, NormanPS, AdamsG3rd. The effect of aerosol distribution on airway responsiveness to inhaled methacholine in patients with asthma. J Allergy Clin Immunol1992;89(2):510–518.
33.
DolovichM, NahmiasC, CoatesG.Unleashing the PET: 3D imaging of the lung. In: ByronP, DalbyR, FarrS, editors. Respiratory Drug Delivery VII. North Carolina: Serenta Publishers; (2000, in press).
34.
WillekeK, BaronPA. Aerosol measurement: principles, techniques and applications. New York: Van Nostrand Reinhold; 1993.
35.
HallworthG.Particle size of therapeutic aerosols. In: MorenF, DolovichM, NewhouseM, NewmanS, editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier; 1993: 351–374.
36.
MeakinBJ, GandertonD, PanzaI, VenturaP.The effect of flow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler. J Aerosol Med1998;11(3):143–152.
37.
SmithKJ, ChanHK, BrownKF. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med1998;11(4):231–245.
38.
PrimeD, GrantAC, SlaterAL, WoodhouseRN. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med1999;12(2):75–84.
39.
PedersenS, HansenOR, FuglsangG.Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child1990;65(3):308–310.
40.
BorgstromL, BondessonE, MorenF, TrofastE, NewmanSP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J1994;7(1):69–73.
41.
BorgstromL, DeromE, StahlE, Wahlin-BollE, PauwelsR.The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med1996;153(5):1636–1640.
42.
DevadasonSG, EverardML, MacEarlanC, RollerC, SummersQA, SwiftP, et al. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J1997;10(9):2023–2028.
43.
DolovichM.Lung dose, distribution and clinical response to therapeutic aerosols. Aerosol Sci Technol1993;18:230–240.
44.
MitchellJP, DolovichMB. A standard for testing of spacers and holding chambers: in vitro testing parameters (abstract). J Aerosol Med1999;12(2):134.
45.
DolovichM, RhemR.In vitro characterization of two BDP HFA PMDIs (abstract). J Aerosol Med1999;12(2):112.
46.
DolovichM, RhemR.In vitro comparison of a BDP HFA PMDI with CFC Beclovent. Eur Respir J1999;14(Suppl 30):197S, P1364.
47.
LeachCL, DavidsonPJ, BoudreauRJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC- beclomethasone. Eur Respir J1998;12(6):1346–1353.
48.
DolovichMB, RhemR, GerrardL, CoatesG.Lung deposition of coarse CFC vs fine HFA PMDI aerosols of beclomethasone dipropionate (BDP) in asthma (abstract). Am J Respir Crit Care Med2000;161 (4 Pt2):A62.
49.
BusseWW, BrazinskyS, JacobsonK, StrickerW, SchmittK, Vanden BurgtJ, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol1999;104(6):1215–1222.
50.
DolovichM, RuffinRE, RobertsR, NewhouseMT. Optimal delivery of aerosols from metered dose inhalers. Chest1981;80(6 Suppl):911–915.
51.
ThorssonL, KenyonC, NewmanSP, BorgstromL.Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm1998;168:119–121.
52.
FokTF, MonkmanS, DolovichM, GrayS, CoatesG, PaesB, et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol1996;21(5):301–309.
53.
BisgaardH.Delivery of inhaled medication to children (review). J Asthma1997;34(6):443–467.
54.
ZanenP, GoLT, LammersJ-WJ. The optimal particle size for parasympathicolytic aerosols in mild asthmatics. Int J Pharm1995;114(1):111–115.
55.
ZanenP, GoLT, LammersJW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax1996;51(10):977–980.
56.
ZanenP, GoLT, LammersJW. The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler. Eur J Clin Pharmacol1998;54(1):27–30.
57.
DolovichM, RhemR, RashidF, BowenB, CoatesG, HillM.Lung deposition of albuterol sulphate from the Dura Dryhaler on normal adults (abstract). Am J Respir Crit Care Med1996;153(4 Pt 2):A62.
58.
DolovichM.New propellant-free technologies under investigation (review). J Aerosol Med1999;12 Suppl1:S9–S17.
JanssensHM, KrigsmanAM, VerbraakAFM, HopWCJ, de JongsteJC, TiddensHAWM. Fine particle size improves lung deposition of inhaled steroids in infants: a study in an upper airway model (abstract). Am J Respir Crit Care Med2000;161(4 Pt 2):A32.
61.
DolovichM, RhemR, KwongJ.Simulating aerosol delivery: effect of particle size, tidal volume and inspiratory flow rate (abstract). Am J Respir Crit Care Med1999;59(4 Pt 2):A615.
62.
EverardM, DolovichM.In vivo measurements of lung dose. In: BisgaardH, O'CallaghanC, SmaldoneG, editors. Lung biology in health and disease series. New York: Marcel Dekker; (in press. 2000).
